Von Willebrand Disease (VWD)
Part 3: VWF Activity Assay
A New von Willebrand Factor Activity Assay and Testing Algorithm
VWF:Lx and VWF:RCo Errors
June 2011
Now let us examine the outliers in detail. 2 of the 3 samples of the normal group and type 2A or 2B group were lipemic. As we know that lipemia could potentially interfere with the optical property of a turbidimetric assay. However, the discrepancy of the remaining 1 sample from the normal and the 1 sample from the type 2A or 2B group can not be clinically verified since they were both Mayo Medical Laboratories samples. This underscores a potential limitation of this assay that it is still uncertain if the new assay will detect all type 2 von Willebrand disease variants, or conversely, if the new assay will pick up new type 2 von Willebrand variants that would have been missed by the VWF ristocetin cofactor activity assay. As for the group of severe types 1 or 2M, we classify the 8 samples by using a highly sensitive flow cytometric method.
VWF:Lx and VWF:RCo Errors |
Jump to section:
- Introduction
- Objectives
- History of VWF Ristocetin Cofactor Activity (VWF:RCo) Assay
- Problems with VWF:RCo Assay
- Summary of External Quality Assessment of VWF:RCo
- von Willebrand Disease(VWD) Diagnostic Error Rates Due to Erroneous VWF:RCo Results5
- VWF:RCo/Ag Ratio is Insensitive for Aquired von Willebrand Abnormalities (AVWA)
- VWF:RCo is Inadequate for Detecting AVW Abnormality
- The New Automated VWF Activity by Latex-Immunoturbidity Assay (VWF:Lx)
- VWF Activity Assay by an A1 Domain Conformation-Sensitive Antibody6
- Performance Characteristics of VWF:Lx
- VWF:Lx and VWF:RCo Method Comparison
- VWF:Lx and VWF:RCo Bias Analysis
- Sample Categorization
- Comparison of VWF:Lx/Ag and VWF:RCo/Ag Ratios
- VWF:Lx and VWF:RCo Errors
- Severe Type 1 vs 2M7
- VWF:Lx and RCo Errors
- VWF:Lx/Ag is Sensitive to AVWA with Subtle Loss of Highest HMWM
- ROC Analysis of VWF:Lx/Ag and VWF:RCo/Ag for Detecting AVWA with Loss of HMWMs
- VWF:Lx/Ag vs VWF:RCo/Ag Ratios
- VWF Laboratory Testing Strategy
- Sensitivity and Specificity of the Screening Panel
- von Willebrand Disease Profile
- von Willebrand Disease Profile
- von Willebrand Disease Profile
- von Willebrand Disease Profile
- Limitations of VWF:Lx
- Summary
- References
- Questions?


